23 April 2019

Patients with a sarcoma belong to a group of patients with rare cancers.

In addition to limited treatment options, there is a poor understanding of sarcomas. The main aim of the Radboud Biobank Sarcoma is to gain insight into prognostic and predictive factors of the different sarcomas. Biomaterial (blood and tissue) in combination with clinical data will be stored in this sub-biobank.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Sub-biobank MEMORY

15 September 2020

The MEMORY biobank focuses on research into biomarkers for memory impairment and dementia and their validation in clinical cohorts.

read more

RYR1 sub-biobank

15 September 2020

The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants.

read more

New colleague

15 September 2020

My name is Robbert Croes and I started mid 2020 as a data-scientist at the Radboud Biobank.

read more

ProBCI sub-biobank

15 September 2020

There is a pressing need for predictive biomarkers to personalize bladder cancer treatment.

read more

Financial regulation for sub-biobanks

15 September 2020

Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.

read more